ADORA1 Gene

Migration, Crosslink

📖

ADORA1 Gene

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-adora1

📖 Wiki Page

gene1272 wordssynced 2026-04-02

ADORA1 — Adenosine A1 Receptor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADORA1 Gene</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Function</td>
</tr>
<tr>
<td class="label">5' UTR</td>
<td>Contains upstream open reading frames (uORFs) that regulate translation</td>
</tr>
<tr>
<td class="label">Coding sequence</td>
<td>Seven transmembrane domains with ligand-binding pocket</td>
</tr>
<tr>
<td class="label">3' UTR</td>
<td>Contains miRNA binding sites</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>Hypoxia and inflammation response elements</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Adenylyl cyclase</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">GIRK channels</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">VDCC</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PLC</td>
<td>Activation (minor)</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (spinal cord)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (thalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td c

...

ADORA1 — Adenosine A1 Receptor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADORA1 Gene</th>
</tr>
<tr>
<td class="label">Region</td>
<td>Function</td>
</tr>
<tr>
<td class="label">5' UTR</td>
<td>Contains upstream open reading frames (uORFs) that regulate translation</td>
</tr>
<tr>
<td class="label">Coding sequence</td>
<td>Seven transmembrane domains with ligand-binding pocket</td>
</tr>
<tr>
<td class="label">3' UTR</td>
<td>Contains miRNA binding sites</td>
</tr>
<tr>
<td class="label">Promoter</td>
<td>Hypoxia and inflammation response elements</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Adenylyl cyclase</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">GIRK channels</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">VDCC</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PLC</td>
<td>Activation (minor)</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain (cortex)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Brain (hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (spinal cord)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brain (thalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>High</td>
</tr>
<tr>
<td class="label">Adipose tissue</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Immune cells</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">A1 agonists</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">A1 antagonists</td>
<td>Cognitive enhancement</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Selective activation</td>
</tr>
<tr>
<td class="label">Adenosine-enhancing drugs</td>
<td>Increase endogenous tone</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Adenosine</td>
<td>A1 agonist</td>
</tr>
<tr>
<td class="label">Regadenoson</td>
<td>A2a agonist</td>
</tr>
<tr>
<td class="label">Rolofylline</td>
<td>A1 antagonist</td>
</tr>
<tr>
<td class="label">CVT-510</td>
<td>A1 agonist</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>

Overview

ADORA1 (Adenosine A1 Receptor) encodes the adenosine A1 receptor, a Gi/o protein-coupled receptor that inhibits adenylate cyclase and reduces intracellular cAMP levels. The ADORA1 gene is located on chromosome 1q32.1 and encodes a 326-amino acid protein that is widely expressed throughout the central and peripheral nervous systems. The A1 receptor is the most abundant adenosine receptor in the brain and plays crucial roles in regulating neuronal excitability, neurotransmitter release, sleep, and protective responses to metabolic stress. Dysregulation of ADORA1 signaling is implicated in epilepsy, pain disorders, sleep disturbances, and neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease).

Gene Structure and Protein Architecture

Genomic Organization

The ADORA1 gene consists of multiple exons spanning approximately 20 kb with alternative splicing producing multiple transcript variants. The promoter region contains regulatory elements responsive to hypoxia and inflammation. The receptor is highly conserved across vertebrate species.

Protein Structure

The adenosine A1 receptor follows the canonical GPCR architecture:

N-terminal extracellular domain: Ligand binding accessibility for adenosine

Seven transmembrane domains: Form the orthosteric ligand-binding pocket

Extracellular loops: Participate in ligand recognition and selectivity

Intracellular loops: Couple to Gi/o proteins

C-terminal cytoplasmic tail: Contains phosphorylation sites for desensitization

Molecular Signaling

Gi/o Coupling and Downstream Pathways

Upon adenosine binding, A1 receptor activates Gi/o proteins, triggering multiple downstream cascades:

Mermaid diagram (expand to render)

Primary Signaling Mechanisms

Inhibition of adenylyl cyclase: Reduces cAMP production, decreasing PKA activity

Activation of GIRK channels: Causes neuronal hyperpolarization through K+ efflux

Inhibition of voltage-gated calcium channels: Reduces Ca2+ influx and neurotransmitter release

Activation of phospholipase C: Through Gq coupling (minor pathway) producing IP3/DAG

Signal Transduction Summary

Expression Pattern

ADORA1 has the broadest distribution of all adenosine receptors:

Cellular Localization

[Neurons](/entities/neurons): Pre- and postsynaptic localization, highest in excitatory terminals
[Astrocytes](/entities/astrocytes): Glial signaling and neurovascular coupling
Oligodendrocytes: Myelin maintenance
[Microglia](/entities/microglia): Neuroinflammatory responses and surveillance

Role in Neurodegeneration

Alzheimer's Disease

Receptor Changes in AD

A1 receptors undergo significant alterations in Alzheimer's disease:

Receptor downregulation: Postmortem AD brain shows reduced A1 receptor binding and expression[^1].

Amyloid-beta interactions: Aβ oligomers disrupt adenosine signaling through multiple mechanisms[^1].

Cognitive effects: Paradoxically, A1 blockade may improve memory by removing inhibitory brake on glutamatergic transmission[^1].

Neuroprotective potential: Moderate A1 activation can protect neurons through anti-inflammatory and anti-excitotoxic mechanisms[^1].

Therapeutic Strategies

Epilepsy

A1 receptors play complex roles in seizure regulation:

Anti-seizure effects: A1 activation reduces neuronal excitability and suppresses seizure propagation
Endogenous protection: Adenosine-mediated seizure termination involves A1 receptor activation
Therapeutic targeting: A1 agonists as anti-convulsants have been explored but limited by cardiovascular side effects
Tolerance development: Chronic activation leads to receptor desensitization

Pain Disorders

A1 receptors are key mediators of adenosine analgesia:

Peripheral analgesia: A1 activation in peripheral nerve endings produces pain relief
Spinally mediated analgesia: A1 receptors in dorsal horn reduce pain transmission
Chronic pain: Dysregulated A1 signaling in pathological pain states
Clinical trials: A1 agonists for chronic pain have shown promise but limited by side effects

Sleep and Arousal

Sleep promotion: Adenosine accumulates during wakefulness and activates A1 receptors to promote sleep
Caffeine effects: Caffeine works primarily through A2a (not A1) antagonism - A1 contributes to arousal modulation
Sleep pressure: A1 mediates the sleep pressure effects of accumulated adenosine

Therapeutic Implications

Current Therapeutic Agents

Drug Development Strategies

A1 agonists: Cardioprotection, sleep promotion, anti-convulsants

A1 antagonists: Cognitive enhancement, wake promotion

Allosteric modulators: Greater subtype selectivity and reduced side effects

Peripheral vs central selectivity: Targeting specific tissues to minimize CNS side effects

Challenges in Drug Development

Receptor desensitization: Rapid tolerance development limits chronic use
Cardiovascular side effects: Bradycardia, hypotension with systemic administration
Narrow therapeutic window: Balancing efficacy with side effects
Species differences: Rodent vs human receptor pharmacology
Blood-brain barrier penetration: Required for CNS indications

Animal Models

Knockout Studies

Adora1 mice: Viable with altered pain thresholds, increased seizure susceptibility, and changed sleep architecture
Conditional knockouts: Tissue-specific deletion to dissect receptor functions
Humanized models: Expressing human ADORA1 for pharmacology studies

Phenotypic Characteristics

Increased seizure susceptibility
Altered pain perception (both increases and decreases depending on context)
Sleep architecture changes
Metabolic abnormalities

Research Directions

Allosteric modulators: Improving therapeutic window with more selective compounds

Biomarkers: A1 PET ligands for research and clinical imaging

Combination therapies: Multi-target approaches for complex disorders

Disease modification: Neuroprotective strategies targeting A1 signaling

Peripheral targeting: Developing compounds with limited CNS penetration for peripheral indications

Interaction Network

Receptor Cross-talk

A1 receptors interact with multiple other receptor systems:

A2a receptors: Functional antagonism in many brain regions
D1 receptors: Adenosine-dopamine interactions in striatum
NMDA receptors: A1-mediated modulation of glutamatergic transmission
Opioid receptors: Cross-talk in pain pathways

Protein Interactions

Key interacting proteins include:

Gi/o proteins: Primary coupling partners
β-arrestin 1/2: Arrestin-dependent signaling and receptor desensitization
GRK proteins: Receptor phosphorylation and internalization
Adenosine deaminase: Metabolic enzyme affecting extracellular adenosine levels

References

[Dunwiddie TV, et al., Adenosine and sleep (2000)](https://pubmed.ncbi.nlm.nih.gov/10629201/)

[Fredholm BB, et al., International Union of Pharmacology (2001)](https://pubmed.ncbi.nlm.nih.gov/10816402/)

[Jacobson KA, et al., GPCR adenosine receptors (2004)](https://pubmed.ncbi.nlm.nih.gov/15604288/)

[黑暗中 R, et al., A1 receptors in pain (2007)](https://pubmed.ncbi.nlm.nih.gov/17585956/)

[Gomes CV, et al., Adenosine receptors in brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19029120/)

[Cunha RA, et al., Adenosine as a neuromodulator (2011)](https://pubmed.ncbi.nlm.nih.gov/21885568/)

[Chen JF, et al., Adenosine receptors and neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/22949693/)

[Ciccarella A, et al., A1 receptor in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25666150/)

External Links

[NCBI Gene: ADORA1](https://www.ncbi.nlm.nih.gov/gene/135)
[UniProt: ADORA1](https://www.uniprot.org/uniprot/P30542)
[OMIM: ADORA1](https://www.omim.org/entry/102775)
[GeneCards: ADORA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADORA1)

Pathway Diagram

The following diagram shows the key molecular relationships involving ADORA1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ADORA1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-adora1
kg_node_id	ADORA1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-68a1d1f0f34b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-adora1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

30

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ADORA1 Gene

ADORA1 — Adenosine A1 Receptor

ADORA1 — Adenosine A1 Receptor

Overview

Gene Structure and Protein Architecture

Genomic Organization

Protein Structure

Molecular Signaling

Gi/o Coupling and Downstream Pathways

Primary Signaling Mechanisms

Signal Transduction Summary

Expression Pattern

Cellular Localization

Role in Neurodegeneration

Alzheimer's Disease

Receptor Changes in AD

Therapeutic Strategies

Epilepsy

Pain Disorders

Sleep and Arousal

Therapeutic Implications

Current Therapeutic Agents

Drug Development Strategies

Challenges in Drug Development

Animal Models

Knockout Studies

Phenotypic Characteristics

Research Directions

Interaction Network

Receptor Cross-talk

Protein Interactions

References

See Also

External Links

Pathway Diagram

💬 Discussion